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Abstract
Background: A novel anticancer drug 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine (ECyd, TAS106) has been
shown to radiosensitize tumor cells and to improve the therapeutic efficiency of X-irradiation. However, the effect
of TAS106 on cellular DNA repair capacity has not been elucidated. Our aim in this study was to examine whether
TAS106 modified the repair capacity of DNA double-strand breaks (DSBs) in tumor cells.
Methods: Various cultured cell lines treated with TAS106 were irradiated and then survival fraction was examined
by the clonogenic survival assays. Repair of sublethal damage (SLD), which indicates DSBs repair capacity, was
measured as an increase of surviving cells after split dose irradiation with an interval of incubation. To assess the
effect of TAS106 on the DSBs repair activity, the time courses of g-H2AX and 53BP1 foci formation were examined
by using immunocytochemistry. The expression of DNA-repair-related proteins was also examined by Western blot
analysis and semi-quantitative RT-PCR analysis.
Results: In clonogenic survival assays, pretreatment of TAS106 showed radiosensitizing effects in various cell lines.
TAS106 inhibited SLD repair and delayed the disappearance of g-H2AX and 53BP1 foci, suggesting that DSB repair
occurred in A549 cells. Western blot analysis demonstrated that TAS106 down-regulated the expression of BRCA2
and Rad51, which are known as keys among DNA repair proteins in the homologous recombination (HR) pathway.
Although a significant radiosensitizing effect of TAS106 was observed in the parental V79 cells, pretreatment with
TAS106 did not induce any radiosensitizing effects in BRCA2-deficient V-C8 cells.
Conclusions: Our results indicate that TAS106 induces the down-regulation of BRCA2 and the subsequent
abrogation of the HR pathway, leading to a radiosensitizing effect. Therefore, this study suggests that inhibition of
the HR pathway may be useful to improve the therapeutic efficiency of radiotherapy for solid tumors.
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Background
Radiation is one of the effective treatments for cancer
therapy. Double-strand breaks (DSBs) in tumor cells
exposed to ionizing radiation are believed to cause
apoptosis, mitotic catastrophe and reproductive cell
death [1,2]. However, because DSBs are immediately
repaired by DNA repair mechanisms, the cellular DNA
repair capacity seems to be closely associated with the
outcome of radiotherapy [3]. Therefore, targeting DNA
DSB repair pathways can be a potential therapeutic
strategy to enhance the antitumor effect of radiation.
In repair mechanisms forD N AD S B s ,t h e r ea r et w o
major pathways, non-homologous end joining (NHEJ)
and homologous recombination (HR). In the NHEJ
pathway, which is active during all phases of the cell
cycle, DNA ends are joined with little or no base dele-
tion at the end-joining site. In contrast, the HR pathway
employs the sister chromatid after DNA replication,
which results in error-free repair. Therefore, HR is most
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way, a large number of proteins are involved, including
Mre11-Rad50-NBS1 (MRN)c o m p l e x ,R P A ,R a d 5 1 ,
BRCA1, and BRCA2. In response to DSBs, Rad51 forms
nucleoprotein filaments on single-strand DNA (ssDNA)
and causes strand exchanges between ssDNA and
homologous double-strand DNA [5]. Therefore, Rad51
acts as a central player in HR and its cellular expression
level affects radiosensitivity and chemosensitivity [6].
BRCA2 phospholylated at Ser3291 directly interacts
with Rad51 through BRC repeats, facilitating the forma-
tion of Rad51 filaments [7,8]. Accordingly, BRCA2 is a
key protein to promote Rad51 recombinase function
after DNA damage. In fact, cells lacking functional
BRCA2 exhibit genomic instability and sensitivity to
DNA-damaging agents such as etopside, bleomycin and
X-rays [9,10].
The ribonucleoside anticancer drug, 1-(3-C-ethynyl-b-
D-ribo-pentofuranosyl)cytosine (ECyd, TAS106) inhibits
RNA synthesis through competitive inhibition of RNA
polymerase (Figure 1) [11]. TAS106 rapidly undergoes
phosphorylation to a 5’-triphosphate form (ECTP) after
its uptake into cells, and ECTP strongly inhibits RNA
polymerase to cause RNA synthesis inhibition [12,13].
Furthermore, Naito et al. have demonstrated that
TAS106 strongly induces JNK-dependent apoptosis
through activation of an RNase L-mediated RNA degra-
dation pathway [14]. In the phosphorylation of TAS106,
uridine/cytidine kinase (UCK) is responsible for the first
phosphorylation of TAS106 to the 5’-monophosphate
form. The UCK activity in tumor cells is higher than
that in non-tumor cells, thereby causing the
accumulation of TAS106 preferentially in tumor cells
[13-16]. We have previously reported that a sublethal
dose of TAS106 strongly suppresses the expression of
anti-apoptotic proteins and G2/M checkpoint-related
proteins, and enhances radiation-induced cell death and
growth delay in gastric tumor cell lines MKN45,
MKN28 and murine rectum adenocarcinoma cell line
Colon26 in vitro [17] and in vivo [18]. Furthermore, this
radiosensitizing effect is also observed in radioresistant
hypoxic cells through the inhibition of hypoxia inducible
factor 1a (HIF-1a) expression [19]. However, the pre-
cise mechanism underlying TAS106-induced radiosensi-
tization remains elusive.
In this study, to further examine the mechanism of
TAS106-induced radiosensitization, we investigated
whether TAS106 could modify the repair capacity of
DNA DSBs. We demonstrate that TAS106 decreases
cellular DNA DSB repair capacity and radiosensitizes
human lung carcinoma A549 cells. In addition, we show
that this radiosensitizing effect is mainly due to abroga-
tion of the HR pathway through the suppression of
BRCA2 expression.
Results
TAS106 enhances radiosensitivity in tumor and
immortalized cells
To determine whether pretreatment with TAS106
enhanced the radiosensitivity of tumor and immortalized
cells, we performed a clonogenic survival assay. Figure
2A shows the X-ray dose-response curves for cell survi-
val in A549 cells pretreated with TAS106 at various
concentrations. Pretreatment with TAS106 suppressed
the clonogenic cell survival in a concentration-depen-
dent manner and the 10% lethal dose (D10)o ft h es u r -
viving fraction was reduced from 7.88 Gy in the control
to 5.24 Gy by the treatment with 1 μM TAS106. The
sensitizer enhancement ratio (SER) judged by the D10
was 1.50, indicating the increase of sensitivity to X-irra-
diation induced by TAS106. In addition, HEp-2 cells
and V79 cells pretreated with TAS106 also exhibited
sensitization to X-irradiation as shown in Figures 2B
and 2C. SER values for HEp-2 and V79 cells were 1.59
and 1.28, respectively. Furthermore, TAS106 increased
the a values in all cell lines tested (Table 1). These
results indicated that pretreatment with TAS106
enhanced radiosensitivity in various cell lines.
TAS106 suppresses cellular DSB repair capacity
To investigate whether TAS106 radiosensitized tumor
cells by inhibiting DNA DSB repair, we measured the
sublethal damage (SLD) repair in A549 cells. The SLD
assay is based on evidence that cell survival increases
with extended interval times between two split doses of
X-rays, provided that the cells can repair the initial
Figure 1 TAS106. The chemical structure of TAS106.
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SLD repair is considered to reflect the cellular DSB
repair capacity. As shown in Figure 3A, the survival
ratio in A549 cells exposed to fractionated irradiation
increased as the interval time extended up to 6 h and
then decreased at 12 h. The maximum increase of the
survival ratio was 1.4 at the 6 h interval time. In con-
trast, there was little increase in the survival ratio of
A549 cells pretreated with TAS106. This result sug-
gested that the pretreatment with TAS106 suppressed
DNA DSB repair in A549 cells.
To further support these data, we analyzed DSBs in X-
irradiated cells by g-H2AX and 53BP1 foci formation
assay. Histone H2AX is known to be phosphorylated at
serine 139 (g-H2AX) immediately after DSB induction,
and then g-H2AX forms nuclear foci in the region of
the DSBs, and subsequently undergoes dephosphoryla-
tion after the repair of DNA strand breaks. p53 binding
protein 1 (53BP1) also localizes at the DSBs region.
Therefore, the numbers of g-H2AX and 53BP1 foci are
used as a measure of the relative amount of DSBs and
repair kinetics [21,22]. When cells were irradiated at 1
Gy, the average number of g-H2AX foci per cell peaked
at 30 min after irradiation and decreased with time for
both cells with or without TAS106 (Figure 3B). There
were no significant differences in the numbers of g-
H2AX foci between cells without and with TAS106 30
min after irradiation. However, at 1 h, 2 h and 6 h after
irradiation, the numbers of foci in cells pretreated with
TAS106 were higher than in cells without TAS106. In
addition, the average number of 53BP1 foci in cells trea-
ted with TAS106 was significantly greater than that in
cells without TAS106 at 6 h after irradiation. These
results suggested that TAS106 inhibited DSB repair.
Figure 2 Effect of TAS106 on radiosensitivity of A549, HEp-2
and V79 cell lines. (A-C) Dose-response curves for cells exposed to
X-irradiation with or without indicated concentrations of TAS106.
After the pretreatment with TAS106, cells were irradiated and
assessed for its radiosensitizing effect by measuring clonogenic cell
survival. (A) Clonogenic cell survival for A549 cells. Closed circle;X -
irradiation only, open circle; X-irradiation + 0.5 μM TAS106, closed
square; X-irradiation + 0.75 μM TAS106, open square; X-irradiation +
1 μM TAS106. (B) Clonogenic cell survival for HEp-2 cells. Closed
circle; X-irradiation only, open square; X-irradiation + 0.1 μM TAS106.
(C) Clonogenic cell survival for V79 cells. Closed circle; X-irradiation
only, open square; X-irradiation + 1 μM TAS106. Data are expressed
as mean ± SE of three experiments.
Table 1 Summary of survival curves parameters
Cell line TAS106 a SERa b SERb D10 SERD10
(μM) (Gy
-1) (Gy
-2) (Gy)
A549 0 0.04 - 0.032 - 7.88 -
0.5 0.04 1.00 0.033 1.03 7.77 1.01
0.75 0.12 3.00 0.033 1.03 6.73 1.17
1 0.12 3.00 0.061 1.91 5.24 1.50
Hep-2 0 0.21 - 0.013 - 7.49 -
0.1 0.41 1.95 0.017 1.31 4.70 1.59
V79 0 0.04 - 0.020 - 9.78 -
1 0.07 1.75 0.030 1.50 7.67 1.28
V-C8 0 0.33 - 0.024 - 5.09 -
1 0.42 1.27 0.020 0.83 4.51 1.13
The data were fitted using the linear-quadratic model, SF = exp(-aD-bD
2). The
10% lethal dose (D10) was calculated from the a and b values. The sensitizer
enhancement ratio (SER) was calculated from the each values with or without
TAS106.
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To explore the mechanism of DSB inhibition by
TAS106, we examined the effect of TAS106 on the
expression levels of DSB repair-related proteins in A549
cells. As shown in Figure 4A, the treatment with 1 μM
TAS106 for 24 h clearly suppressed the expression levels
of BRCA2 and Rad51, which are the key proteins of the
HR pathway. The expression levels of Mre11 and NBS1,
which are constituent proteins of the MRN complex,
were slightly reduced by TAS106. On the other hand,
there was no obvious change in the expression levels of
DNA-PKcs and Ku70, which are involved in the NHEJ
pathway. It has been reported that TAS106 inhibits
RNA synthesis and regulates the expression of its target
proteins at the mRNA level [12,13]. Therefore, we
examined the effect of TAS106 on the mRNA expres-
sion levels of DSB repair-related proteins using semi-
quantitative RT-PCR. Figure 4B shows that the
treatment with 1 μM TAS106 suppressed the mRNA
levels of BRCA2, Rad51, Mre11 and NBS1 in a time-
dependent manner. However, the mRNA levels of DNA-
PKcs and Ku70 were not changed. These tendencies had
good correlation with the results of Western blot analy-
sis. These results suggested that TAS106 suppressed
HR-related proteins but not NHEJ-related proteins.
Down-regulation of BRCA2 and Rad51 was maintained for
12 h after the removal of TAS106
For TAS106-induced down-regulation of BRCA2 and
Rad51 to result in tumor radiosensitization, it needs to
be maintained during the period of initial DSB repair
after X-irradiation. Therefore, we assessed how long this
inhibitory effect was prolonged after the removal of
TAS106. A549 cells were treated with 1 μM TAS106 or
vehicle for 24 h and replaced with fresh medium. After
exposure to X-rays at 10 Gy, cells were collected at each
time point. In cells exposed to X-irradiation alone there
was no change in the expression levels of BRCA2 and
Rad51 (Figure 5A). In contrast, TAS106 reduced the
expression levels of BRCA2 and Rad51 and this per-
sisted up to 12 h after X-irradiation (Figure 5B). These
results suggested that TAS106 reduced the expression
levels of HR-related proteins for a period long enough
to inhibit the repair of radiation-induced DSBs after its
removal.
Down-regulation of BRCA2 is responsible for the
radiosensitizing effect of TAS106
Based on the results described above, we hypothesized
that the radiosensitizing effect of TAS106 was mainly
due to abrogation of the HR pathway through the
down-regulation of BRCA2. To test this hypothesis, we
next compared the radiosensitizing effect of TAS106 in
BRCA2-deficient V-C8 cells with that in parental V79
Figure 3 TAS106 suppressed DNA repair capacity in A549 cells.
(A) Survival ratio of A549 cells after fractionated irradiation. Cells
were pretreated with TAS106 (1 μM) for 24 h and then irradiated
(2.5 Gy). After incubation for the indicated times, they were
irradiated (2.5 Gy) again and cultured for colony formation. The
survival ratios were normalized to unity at time 0 h for each group.
Data are expressed as mean ± SE of three experiments. *p < 0.05,
significant difference by the Mann-Whitney U test. (B) g-H2AX and
(C) 53BP1 focus formation after X-irradiation. Cells were pretreated
with TAS106 (1 μM) for 24 h, followed by X-irradiation (1 Gy). They
were then fixed at the indicated times to evaluate the nuclear g-
H2AX focus formation. The numbers of foci in at least 20 cells were
scored and the average numbers were plotted in the graph. Data
are expressed as mean ± SE of three experiments. *p < 0.05,
significant difference by Student’s t-test.
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that the HR-pathway-mediated DNA damage repair is
impaired in BRCA2-deficient V-C8 cells [23]. While a
significant radiosensitizing effect by TAS106 was
observed in V79 cells, the treatment with 1 μM TAS106
did not induce any radiosensitizing effect in V-C8 cells
(Figure 6). In V79 cells, the pretreatment with 1 μM
TAS106 reduced the D10 of the surviving fraction from
9.78 Gy to 7.67 Gy and its SER was 1.28. In V-C8 cells,
the D10 of the surviving fraction was reduced from 5.09
Gy to 4.51 Gy and SER was 1.13. In addition, SER calcu-
lated from a value in V79 cells was also higher than
that in V-C8 cells (Table 1). Therefore, this result sug-
gested that down-regulation of BRCA2 by TAS106 sup-
pressed the HR pathway of DSB repair, leading to the
radiosensitizing effect.
Discussion
The DNA repair pathway is a promising target for can-
cer radiotherapy because intrinsic DNA repair pathway
enables tumor cells to survive by repairing radiation-
induced DNA lesions. Therefore, there have been sev-
eral studies aimed at radiosensitizing tumor cells by
modulating DNA repair-related molecules. For example,
the ATM inhibitor KU-55933 shows high specificity and
induces radiosensitizing effects in tumor cells [24].
Gemcitabine and Gimeracil, which disrupt the metabolic
pathway for nucleic acids, were also reported to have
radiosensitizing effects through the inhibition of HR-
mediated DSB repair [25,26].
We have previously reported that TAS106 enhances
X-irradiation-induced apoptosis and reproductive cell
death regardless of p53 status in tumor cells in vitro
Figure 4 TAS106 suppressed the expression of BRCA2 and Rad51 at protein and mRNA levels in A549 cells. (A) Effects of TAS106 on the
expression levels of DNA repair-related proteins. Cells were treated with TAS106 (1 μM) for 12 or 24 h. After incubation, cell extracts were
analyzed by Western blotting using specific antibodies. Actin was used as a loading control. (Left) Representative blots of three separate
experiments are shown. (Right) Bands corresponding to each protein were quantified, and intensities of each protein were normalized to the
intensity of actin. Data are expressed as mean ± SE of three experiments. (B) Effects of TAS106 on the mRNA expression levels of DNA repair-
related proteins. Cells were treated with TAS106 (1 μM) for 12 or 24 h. After incubation, total RNA was isolated and the mRNA expression was
analyzed by RT-PCR. Actin was used as an internal control. (Left) A representative image of three separate experiments is shown. (Right) Bands
corresponding to each mRNA were quantified, and the intensity of each mRNA was normalized to the intensity of actin. Data are expressed as
mean ± SE of three experiments.
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key protein regulating apoptosis, and the abrogation of
arrest at the G2/M phase by TAS106 are partly respon-
sible for the enhancement of cell death [16]. Further-
more, TAS106 enhances X-irradiation-induced apoptosis
even under hypoxic conditions through the down-regu-
lation of HIF-1a [18]. Although TAS106 exhibits a clear
radiosensitizing effect, its effect on DNA DSBs, which
are the most lethal DNA lesions caused by X-irradiation,
has not been evaluated yet. Therefore, we assessed the
effect of TAS106 on the repair of radiation-induced
DSBs.
In the present study, pretreatment with TAS106
enhanced radiation-induced cell death in tumor cell
lines A549 and HEp-2 as well as the immortalized cell
line V79 (Figure 2). To determine whether this radio-
sensitizing effect by TAS106 could be explained by the
suppression of DNA repair capacity, we next
investigated the effect of TAS106 on SLD repair. It has
been reported that SLD repair reflects the cellular DSBs
repair capacity mediated by the HR pathway [27,28]. As
shown Figure 3A, TAS106 suppressed the SLD repair in
A549 cells exposed to fractionated irradiation. In addi-
tion, the average numbers of radiation-induced g-H2AX
and 53BP1 foci in TAS106-pretreated cells were higher
than in control cells up to 6 h after X-irradiation, as
s h o w ni nF i g u r e3 Ba n d3 C .T hese results suggested
that TAS106 suppressed DSB repair through inhibition
of the HR pathway.
To clarify the molecular mechanisms of DSB repair
inhibition by TAS106, we tested the effect of TAS106
on the expression levels of DSB repair-related proteins
using Western blot analysis. The expression of NHEJ-
related proteins, DNA-PKcs and Ku70, was not affected
by TAS106. On the other hand, TAS106 suppressed the
expression of the HR-related proteins BRCA2 and
Rad51 (Figure 4A). Therefore, our results suggested that
down-regulation of Rad51 and BRCA2 by TAS106
inhibited the HR pathway, leading to the radiosensitizing
effect, as shown in Figure 2. RAD51 is a crucial compo-
nent of the HR pathway and its down-regulation
enhances radiosensitivity in tumor cells [29,30]. It has
also been reported that deficiency or down-regulation of
BRCA2 results in high sensitivity to X-irradiation due to
Figure 5 Duration of the down-regulation of BRCA2 and Rad51
by TAS106 in A549 cells. Cells were pretreated with or without
TAS106 (1 μM) for 24 h. They were irradiated (10 Gy) and incubated
for the indicated times in the absence of TAS106. After incubation,
cell extracts were analyzed by Western blotting using specific
antibodies. Actin was used as a loading control. (A) X-irradiation
alone and (B) X-irradiation after pretreatment with TAS106.
Representative blots of three separate experiments are shown.
Figure 6 Deletion of BRCA2 abrogated the radiosensitizing
effect of TAS106. Chinese hamster V79 and BRCA2-deficient V-C8
cells were pretreated with or without TAS106 (1 μM) for 6 h and its
radiosensitizing effect was assessed by measuring clonogenic cell
survival. Closed circle; X-irradiation for V79, open circle; X-irradiation +
1 μM TAS106 for V79, closed square; X-irradiation for V-C8, open
square; X-irradiation + 1 μM TAS106 for V-C8. Data are expressed as
mean ± SE of three experiments.
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that loss of HR capacity in BRCA2-deficient cells was
restored by overexpression of wild-type Rad51 [32,33].
Therefore, although TAS106 reduced the expression
levels of BRCA2 and Rad51, it might be possible that
the down-regulation of Rad51 by TAS106 is more influ-
ential than that of BRCA2.
Down-regulation of BRCA2 and Rad51 was main-
tained up to 12 h after the removal of TAS106 and the
following X-irradiation (Figure 5B). As shown in Figure
3B, DSBs were mostly repaired within 6 h after irradia-
tion in control cells. Therefore, the maintenance of this
down-regulation likely contributed to the inhibition of
DSB repair by TAS106. Additionally, TAS106 reduced
the mRNA levels of HR-related proteins in consistent
with the result of Western blot analysis in A549 cells
(Figure 4). These results suggested that TAS106 down-
regulated these proteins transcriptionally, and supported
the results that TAS106 inhibited RNA transcription by
suppressing RNA polymerase II in previous studies
[34-36].
To further support our findings, we compared the
radiosensitizing effect of TAS106 in BRCA2-deficient V-
C8 cells with that in parental V79 cells. TAS106 sensi-
tized V79 cells, but not V-C8 cells, to X-irradiation (Fig-
ure 6). In addition, we examined the effect of TAS106
on the expression level of Rad51 in V79 and V-C8 cells.
TAS106 did not change it in both cells (data not
shown). These results suggested that the down-regula-
tion of BRCA2, rather than Rad51, was primarily attri-
butable to the suppression of cellular DNA repair
capacity and the radiosensitizing effect in TAS106-trea-
ted cells.
Conclusions
We have demonstrated that TAS106 suppresses the
repair of radiation-induced DSBs and enhances radio-
sensitivity, which is mainly associated with the inhibition
of HR pathway through the down-regulation of BRCA2.
DSBs are the main target of cancer radiotherapy, and
targeting inhibition of DNA repair is one approach to
improve the efficiency of it. Therefore, TAS106 could be
a good molecular candidate to achieve it, and the com-
bination of TAS106 and X-irradiation may be an effec-
tive strategy for enhancing tumor cell death.
Methods
Reagents
RPMI 1640, DMEM and a-MEM medium were pur-
chased from Invitrogen (Carlsbad, CA). Ham’sF - 1 0
medium and fetal bovine serum were purchased from
Sigma-Aldrich (St. Louis,M O ) .1 - ( 3 - C - e t h y n y l - b-D-
ribo-pentofuranosyl) cytosine (TAS106) was synthesized
as described elsewhere [11]. The following antibodies
were used for Western blotting and immunostaining:
anti-BRCA2 (Merck, Darmstadt, Germany), anti-NBS1
(Novus Biologicals, Littleto n ,C O ) ,a n t i - M r e 1 1 ,a n t i -
53BP1 (Abcam, Cambridge, MA), anti-g-H2AX (Milli-
pore, Billerica, MA), anti-Rad51, anti-DNA-PKcs, anti-
Ku70, anti-actin, HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), Alexa
Fluor
® 488 anti-mouse IgG and anti-rabbit IgG (Invitro-
gen). The chemiluminescence detection kit, Western
Lightning
® Plus-ECL, was purchased from Perkin Elmer
(Boston, MA).
Cell culture, X-irradiation and drug treatment
Human lung carcinoma cell line A549, human larynx
squamous carcinoma cell line HEp-2 and Chinese ham-
ster fibroblast cell line V79 were grown in RPMI 1640,
DMEM and a-MEM medium containing 10% fetal
bovine serum at 37°C in 5% CO2, respectively. Chinese
hamster fibroblast cell line V-C8, derived from V79, was
g r o w ni nH a m ’s F-10 medium containing 10% fetal
bovine serum. X-irradiation was performed with a Shi-
madzu PANTAK HF-350 X-ray generator (1.0 mm Al
filter, 200 kVp, 20 mA, Shimadzu, Kyoto, Japan). Cells
w e r et r e a t e dw i t hT A S 1 0 6f o r6h( V 7 9a n dV - C 8 )o r
24 h (A549 and HEp-2) and subsequent X-irradiation
was performed in the absence of TAS106.
Clonogenic survival assay
Cells were seeded on 6-cm dishes and treated with
TAS106 at the indicated concentrations for 6 h or 24 h.
Then they were washed twice with PBS and replaced
with fresh medium. Immediately after replacement, cells
were exposed to X-rays and incubated for 7-14 days.
Following this they were then fixed with methanol and
stained with Giemsa solution (Sigma-Aldrich). Colonies
containing more than 50 cells were scored as surviving
cells. In A549 cells, 64, 48 and 29% of cells were alive at
the concentration of 0.5, 0.75 and 1 μM TAS106,
respectively. In addition, cell survivals after TAS106
treatment were 25, 98, and 35% at 0.1 μM for HEp-2, 1
μMf o rV 7 9a n d1μM for V-C8, respectively. Each sur-
viving fractions were corrected using these cell survivals.
The survival curves were fitted to a linear-quadratic
model by data analysis software Origin Pro 7 (OriginLab
Co. Northampton, MA).
Sublethal damage (SLD) repair capacity was measured
as the increase of surviving cells after irradiation with a
split dose at the indicated interval. Cells treated with 1
μM TAS106 for 24 h were washed twice with PBS and
replaced with fresh medium. Immediately after replace-
ment, cells were exposed to X-rays (2.5 Gy) and incu-
bated for 0-12 h for the repair of SLD. At the indicated
times, the cells were exposed to X-rays (2.5 Gy) again
and incubated for 10 days.
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At the indicated times after TAS106 treatment and X-
irradiation, cells attached on glass coverslips were fixed
in 4% paraformaldehyde/PBS for 30 min at room tem-
perature. After being permeabilized with PBS containing
0.5% Triton X-100 for 5 min at 4°C, cells were treated
with PBS containing 6% goat serum for 30 min at room
temperature. Then they were incubated with the anti-g-
H2AX antibody at a 1:500 dilution or the anti-53BP1
antibody at a 1:1000 dilution in 3% goat serum over-
night at 4°C. Cells were then incubated in the dark with
the Alexa Fluor
® 488-conjugated anti-mouse or anti-
rabbit secondary antibody at a 1:500 dilution for 1.5 h.
After incubation, they were counterstained with 300 nM
4’,6’-diamidino-2-phenylindole (Invitrogen) for 5 min at
room temperature. Coverslips were mounted with Pro-
long Gold antifade reagent (Invitrogen). Fluorescent
microscopic analysis was performed using an Olympus
BX50 microscope with reflected light fluorescence and
foci were counted manually.
SDS-PAGE and Western blotting
Cells were collected and lysed in lysis buffer (20 mM
HEPES-NaOH [pH 7.4], 2 mM EGTA, 50 mM glycero-
phosphate, 1% Triton X-100, 10% glycerol, 1 mM
PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin and 10
μg/ml pepstatin). After centrifugation at 15,000 rpm for
15 min at 4°C, supernatants were collected. Three-fold
concentrated Laemmli’s sample buffer (0.1875 M Tris-
HCl [pH 6.8], 15% b-mercaptoethanol, 6% SDS, 30% gly-
cerol and 0.006% bromophenol blue) was added to the
supernatant, and samples were boiled for 5 min. Pro-
teins were separated by SDS-PAGE and transferred onto
an i t r o c e l l u l o s em e m b r a n e( A D V A N T E CT o y o ,T o k y o ,
Japan). The membrane was probed with specific antibo-
dies diluted with TBST (10 mM Tris-HCl [pH 7.4], 0.1
M NaCl and 0.1% Tween-20) containing 5% nonfat skim
milk overnight at 4°C. After being probed with HRP-
conjugated secondary antibodies, bound antibodies were
detected with Western Lightning
® Plus-ECL.
Semiquantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted and purified with an RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. One microgram of RNA was
reverse transcribed using the Reverse Transcription Sys-
tem (Promega Corporation, Madison, WI) and cDNA was
amplified with GoTaq™ DNA Polymerase (Promega). The
specific primer sequences for PCR were as follows: for
BRCA2, 5’-CAAGCAGATGATGTTTCCTGTCC-3’ and
5’-AGAACTAAGGGTGGGTGGTGTAGC-3’; for Rad51,
5’-TTTGGAGAATTCCGAACTGG-3’ and 5’-AGGAA-
GACAGGGAGAGTCG-3’; for Mre11, 5’-CTTGTAC-
GACTGCGAGTGGA-3’ and 5’-TTCACCCATCCC
TCTTTCTG-3’;f o rN B S 1 ,5 ’-AGAAATTGAGTTCCG-
CAGTTGTC-3’ and 5’-GGGATTCTCATCTTAGC-
CAAAG-3’;f o rD N A - P K c s ,5 ’-ACACCATGTCCCAA
GAGGAG-3’ and 5’-AGCCTCAGGGCTTGTACTCA-3’;
for Ku70, 5’-TATTTACGTCTTACAGGAGC-3’ and 5’-
GCATCTTCCTTTTATCATCA-3’; for actin 5’-GACC-
CAGATCATGTTTGAGACC-3’ and 5’-GGTGAG-
GATCTTCATGAGGTAG-3’.
The PCR protocol was as follows: initial denaturation
at 95°C for 2 min, followed by 31 cycles (BRCA2,
Mre11, NBS1, DNA-PKcs, Ku70 and actin) or 40 cycles
( R a d 5 1 )a t9 5 ° Cf o r1m i n ,a n n e a l i n ga t5 5 ° C( K u 7 0 ) ,
60.6°C (NBS1 and Mre11), 63°C (DNA-PKcs and actin),
64°C (Rad51) or 65°C (BRCA2) for 1 min and extension
at 72°C for 1 min. The final extension was performed by
incubation at 72°C for 5 min. The PCR products were
subjected to agarose gel electrophoresis and visualized
using ethidium bromide (Sigma-Aldrich).
List of abbreviations
ATM: ataxia telangiectasia mutated; DSBs: DNA double strand breaks; TAS106:
1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd); HIF-1α: hypoxia
inducible factor-1α; HR: homologous recombination; MRN: Mre11-Rad50-
NBS1; NHEJ: non-homologous end joining; SLD: sub-lethal damage; ssDNA:
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